Abstract:e21055 Background: PD-L1 is a recommended biomarker for immunotherapy, but Some patients with high pD-L1 expression had poor clinical response. Considering the inconsistent correlation between PD- L1 expression and ICI efficacy, A more sensitive biomarker is needed to predict immunotherapy efficacy. B-cell lymphoma-2 (BCL2L11/BIM) belongs to the Bcl-2 family and is a key factor promoting apoptosis. BIM deletion polymorphism (BIM- del) may lead to BH3 deletion and thus hinder cell apoptosis. Loss and decreased expression of BIM may lead to resistance to tumor therapy. A study on patients with metastatic melanoma found that the high level of BIM in CD8+ T cells suggests a stronger PD-1 and PD-L1 interaction, which predicts clinical benefit in patients with metastatic melanoma receiving anti-PD-1 therapy.This study aims to evaluate the relationship between BIM deletion and PD-1/PD-L1 inhibitors efficacy in advanced NSCLC patients. Methods: Patients diagnosed with advanced stage NSCLC that treated with Immune checkpoint inhibitors (ICIs) at Shandong Cancer Hospital between March 2019 and January 2021 were enrolled in this study. Peripheral blood samples from these patients were collected to detect BIM-del by polymerase chain reaction. Cox proportional hazards models were used to analyze the clinical outcomes of patients with and without BIM-del. Results: A total of 61 patients with advanced NSCLC who received immunotherapy were enrolled, only 18.0% (11/61) patients were detected with BIM-del. Most of the patients were male (73.8%, 45/61), younger than 65 years (72.1%, 44/61), non- smokers (50.8%, 31/61), previous treatment lines 0-1 (90.2%, 55/61),had Eastern Tumor Cooperative group (ECOG) performance status (PS) 0-1 (98.4%, 60/61). There were no associations between the BIM-del and clinical characteristics. There was no difference in the objective response rate between patients with and without BIM-del (27.3% vs 30 %, p = 1.000).BIM-del is associated with shorter progression-free survival (PFS) (5.7 months vs12.0 months, p = 0.001). The median OS had not been reached. Multivariate analysis suggested that BIM-del was an negative independent prognostic factor for PFS in immunotherapy patients with non-small cell lung cancer, but not for OS. Conclusions: BIM-del may be a negative prognostic biomarker for patients with advanced NSCLC treated with immunosuppressive therapy. It is very important to find effective and accurate biomarkers to predict the PD-1/PD-L1 inhibitors Treatment efficacy, and further exploration is needed in the future.

The Relationship Between BIM Deletion Polymorphism and Clinical Significance of Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy: a Meta-Analysis.

Exploratory Cohort Study and Meta-Analysis of BIM Deletion Polymorphism in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small-cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

The Effect of BIM Deletion Polymorphism on Intrinsic Resistance and Clinical Outcome of Cancer Patient with Kinase Inhibitor Therapy

Relation of the BIM Deletion Polymorphism to Intrinsic EGFR-TKI Resistance of Chinese Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer.

Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients.

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis.

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer with Sensitive EGFR Mutations

A Systematic Review and Meta-Analysis of Individual Patient Data on the Impact of the Bim Deletion Polymorphism on Treatment Outcomes in Epidermal Growth Factor Receptor Mutant Lung Cancer

Bim Deletion Polymorphism and the Clinical Outcome of Patients with Advanced Nsclc Who Received First-Line Platinum-Based Chemotherapy: Preliminary Results.

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

EGFR-TKIs Plus Chemotherapy Demonstrated Superior Efficacy Than EGFR-TKIs Alone As First-Line Setting in Advanced NSCLC Patients with EGFR Mutation and BIM Deletion Polymorphism.

Association Between Bim Deletion Polymorphism And The Risk Of Non-Small Cell Lung Cancer In Chinese

BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review

The association between BIM deletion polymorphism and treatment efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC.

Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations

The BCL2L11 Deletion Polymorphism is Not Associated with Imatinib Resistance in Chronic Myeloid Leukemia Patients: Meta-Analysis.

Association between BCL-2 (-938C>A) polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated patients with advanced non-small cell lung cancer

The Germline BIM Deletion Polymorphism is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.